Drug Profile
AZD 8233
Alternative Names: AZD-8233; ION-449; IONIS-AZ4-2.5-LRxLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Developer AstraZeneca; Ionis Pharmaceuticals
- Class Antihyperlipidaemics; Antisense oligonucleotides; Cardiovascular therapies; Small molecules
- Mechanism of Action PCSK9 protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
Most Recent Events
- 08 Mar 2023 Discontinued - Phase-I for Dyslipidaemias (In volunteers) in USA (PO)
- 08 Mar 2023 Discontinued - Phase-I for Hypercholesterolaemia in USA (SC)
- 08 Mar 2023 Discontinued - Phase-I/II for Dyslipidaemias (Treatment-experienced) in Japan (SC)